Review Article
Local Chemotherapy for Retinoblastoma
Hussain Ahmed Khaqan, Abdul Hye
Pak J Ophthalmol 2017, Vol. 33, No.
4
. . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . .. . .. . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . .
See end of article for authors affiliations
..
.. Correspondence to: Hussain Ahmed Khaqan Assistant professor FCPS, FCPS (VR), FRCS LGH/ PGMI LAHORE Email: dr.khaqan@hotmail.com |
The new treatment modalities
of retinoblastoma have been very effective in saving the vision, salvaging
the globe and improving the life expectancy of patients. The treatment
options include chemotherapy, that can be intravenous chemotherapy,
periocular chemotherapy, intravitreal chemotherapy and intra-arterial
chemotherapy, and local modalities i.e. transpupillary thermotherapy,
cryotherapy, laser photocoagulation, radiation treatment using plaque
brachytherapy or external beam radiation therapy (EBRT). The most common
intravenous chemotherapy drugs are carboplatin, vincristine, and etoposide.
The drugs for periocular chemotherapy are Topotecan and carboplatin. For
intravitreal chemotherapy the most commonly used drugs are methotrexate,
topotecan and melphalan. For
intra-arterial chemotherapy drugs used are melphalan, topotecan and rarely
carboplatin. The treatment options can be used as single treatment or as
adjuvant to consolidate treatment, depending upon the stage of disease.
Advanced stages of disease and orbital involvement have poor prognosis Key words:
Retinoblastoma, Chemotherapy, Treatment. |
In childhood
malignancies Retinoblastoma (Rb) is the most common intraocular malignancy. It
is more common in children before three years of age. Retinoblastoma may be
unilateral or bilateral, unilateral retinoblastoma is more common. It may be heritable or non-heritable.
Retinoblastoma may present as endophytic or exophytic tumor. Diagnostic methods
include examination under anesthesia, indirect ophthalmoscopy, B scan, CT scan,
MRI scan and retcam imaging. Treatment of retinoblastoma is improving its
outcomes and there is lot of progress. The new treatment modalities of treating
retinoblastoma have been very effective in saving the vision, salvaging the
globe and improving the life expectancy of patients1. The treatment
options include chemotherapy, that can be intravenous chemotherapy, periocular
chemotherapy, intravitreal chemotherapy and intra-arterial chemotherapy, and
local modalities i.e. transpupillary thermotherapy, cryotherapy, laser
photocoagulation, radiation treatment using plaque brachytherapy or external
beam radiation therapy (EBRT). The most common intravenous chemotherapy drugs
are carboplatin, vincristine, and etoposide. The drugs for periocular
chemotherapy are Topotecan and carboplatin. For intravitreal chemotherapy the most
commonly used drugs are methotrexate, topotecan and melphalan. For intra-arterial chemotherapy drugs used
are melphalan, topotecan and rarely carboplatin. The treatment options can be
used as single treatment or as adjuvant to consolidate treatment, depending
upon the stage of disease. Advanced stages of disease and orbital involvement
have poor prognosis.
CLINICAL FEATURES
Patients with Retinoblastoma (RB) may
have different clinical presentations including strabismus and leukocoria. In
initial evaluation, it is important to differentiate RB from other similar
diseases by using ultrasonography. Coats disease, toxocariasis and persistent fetal
vasculature (PFV) are common differential diagnosis of RB. Recently 111 cases
were analyzed for suspected RB, in which 68% patients were found to have RB,
while rest of the 32% patients had other diseases with an alternate diagnosis
of (PFV) 31% and Coats disease (29%)2.
Classification
of retinoblastoma has changed with advancement in treatment strategies. In the past
Reese-Ellsworth (RE) classification of retinoblastoma has been used to predict
globe salvage and external beam radiation was the primary treatment modality at
that time3. However, the R-E classification didnt address sub-retinal
and vitreous seeding. In order to predict better treatment outcomes, a modified
classification was developed by adopting local consolidation treatment and
chemo reduction. Thus, the International Classification of Retinoblastoma was
developed, with primary focus on focal and diffuse vitreous and sub-retinal
seeds4,5.
EPIDEMIOLOGY
In pediatric ocular malignancies, RB is
highly curable tumor6. Many epidemiological studies on RB showed
that tumor affects 1 in 16000-18000 births approximately while 7000-8000 new RB
cases are being reported annually worldwide7,8.
Retinoblastoma
is an important primary intraocular tumor. The annual incidence rate of
retinoblastoma is approximately 3.5 per million for children younger than 15
years of age9 and 11.8 per million for children younger than 4 years5,7.
The combined incidence rate for children younger than 14 is estimated to be 53
60 per million6,9. In United States the survival rate approaches
100% while in other developing countries it is much lower. Survival rate is 80
89%10-20, 83%17, 81%18,19 and 48% in Latin
America, Iraq, China and India respectively20. It is much lower 20 46% in Africa21,22.
Additionally, with the increasing population, especially in Africa and Asia,
retinoblastoma is getting more importance6.
TREATMENT
The treatment options having less
systemic side effects, better outcomes in term of saving vision, salvaging the
eye and improving the life expectancy of the patient are getting more
popularity and are used more frequently mostly in first world countries. Local
chemotherapy is more targeted and is discussed further:
Selective Intra‑Arterial Chemotherapy: (SIAC)
The need of selective intra-arterial chemotherapy is very
high because of less systemic side effects although systemic chemo therapy and
consolidation with focal treatments may have good treatment outcomes but on the
other hand systemic chemotherapy may have very fatal side effects, so selective
intra-arterial chemotherapy (SIAC) is one of the best options in which
chemotherapy drug is delivered to the eye through ophthalmic artery and it is
most targeted19. SIAC has minimal side effects as compared to
systemic chemotherapy. In Japan in 2004, scientists used a novel technique
named as Selective Ophthalmic Artery Infusion (SOAI), in which drug was
delivered at distal part of ophthalmic artery through trans femoral approach20,21.
SOAI was later modified by Abramson and Gobin in which chemo drug was delivered
in ophthalmic artery that was more precise and he named it super selective intra-arterial
chemotherapy (SIAC)22. The drug used by them was Melphalan for SIAC
and no serious side effects were observed. Gobin et al used SIAAC in bilateral
and unilateral advanced stage23. SIAC has high safety in terms of
systemic and local side effects24. Role of IAC in recurrent disease
was studied and it was observed that SIAC with melphalan alone or combined with
Topotecan has very encouraging outcomes and tumor control was achieved in 75%
of cases and in 67% cases the globe was successfully salvaged25.
Chen M et al. presented the IAC outcomes in infants less
than three months of age. Tumor regressed in 12 eyes out of 13 after 28 months.
They reported this treatment as very promising
for infants less than three months having retinoblastoma26.
Shields et al studied the outcomes of
IAC with melphalan in cases where intra-vitreal
melphalan was given before or after IAC. They observed high success in globe salvage
when IAC is consolidated with intra vitreal chemotherapy27. Leal‑Leal et al. gave topotecan and
melphalan combine SIAC in advanced stages of tumor and they reported 55% prevention
of enucleation in their patients28.A short study conducted in India
showed complications and outcomes of SIAC in local patients. They used
melphalan (3 mg/5 mg/7.5 mg) and topotecan (1 mg) (n = 4) or melphalan (3 mg/5
mg/ 7.5 mg) alone (n = 2). A mean of three IAC sessions were given in each eye.
They observed vitreous hemorrhage and diffuse choroidal atrophy in one case and
they had good treatment response29.
Periocular Chemotherapy
Carboplatin
injection has been used for control of RB as periocular therapy along with
systemic chemotherapy. Periocular injection of Topotecan 0.18 mg/kg has
been advocated in recent years in adjuvant with systemic chemotherapy. In
comparison with intravenous route, same level of periocular chemotherapy can be
achieved in 30 min within vitreous and doses that are 6 10 times that of
intravitreous route with effect lasting for hours. To deliver the chemotherapy common
route being used are subconjunctival or subtenons space location. Because of
recurrences of disease, periocular therapy is usually combined with systemic
therapy in order to enhance the local dose in vitreous. Complications of this
local therapy include ecchymosis, periocular edema, ocular muscle fibrosis
causing squint, atrophy of orbital fat and optic disc atrophy. Long-term
complications have not observed and yet to be published30.
Intravitreal Chemotherapy
Vitreous seeds usually respond poorly to systemic chemotherapy,
because of low drug concentration in vitreous due to being an avascular
structure. Intra-vitreal chemotherapy is basically used as salvage therapy in
cases of persistent vitreous seeds31. The recommendations by Inomata
and Kaneko were that melphalan is the most effective drug for seeds in
retinoblastoma33.
Munier et al33 also used melphalan for vitreous seedlings
in retinoblastoma in a dose of 20 30 ΅g/ 0.1 ml. The technique of
intravitreal injection of melphalan was given 3-3.5 mm from limbus and triple
thaw cryotherapy was done at injection site soon after taking out the needles
to prevent needle tack seeding. The globe is rotated so that drug may be
distributed in the vitreous equally. Shield et al described high success rate of
intravitreal chemotherapy and showed 100 percent results in 24 months follow
up.34 Topotecan can also be used for intra-vitreal chemotherapy in
vitreous seedlings in concentration of 8 20 ΅g/0.04 ml and it has longer half-life
than melphalan. Combination of intra-vitreal chemotherapy is also practiced. The
effect of intravitreal topotecan (8 20 ΅g of topotecan
dissolved in 0.04 mL of balanced salt solution) combined with melphalan (40 ΅g
of melphalan in 0.04 mL of diluent) was found to be safe in 9 eyes by Ghassemi
et al35. There are side effects of intra-vitreal chemotherapy that
have been studied by different authors and found that safe dose 20 30 ΅g has preservation
of normal retinal functions as studied on electroretinogram (ERG), while others
reported decreased ERG amplitudes indicating permanent retinal toxicity36.
CONCLUSION
Local
chemotherapy for retinoblastoma is safe and effective.
Dr. Hussain
Ahmed Khaqan
Assistant
professor
FCPS, FCPS
(VR), FRCS
LGH/ PGMI, Lahore
Dr. Abdul Hye
Professor
FCPS, MCPS
LGH/ PGMI, Lahore
Role of Authors
Dr. Hussain
Ahmed Khaqan
Article
writing.
Dr. Abdul Hye
Proof reading
and critical review.
REFERENCES
1. Chawla B, Jain A, Seth R, Mohan VK, Pushker
N, et al. Clinical outcome and regression patterns of retinoblastoma
treated with systemic chemoreduction and focal therapy: A prospective study.
Indian J Ophthalmol. 2016; 64: 524-9.
2. Maki JL, Marr BP, Abramson DH.
Diagnosis of retinoblastoma: how good are referring physicians? Ophthalmic Genet.
2009; 30: 199205.
3. Reese AB, Ellsworth RM. The evaluation and
current concept of retinoblastoma therapy. Trans Am Acad Ophthalmol Otolaryngol.
1963; 67: 164172.
4. Linn Murphree A. Intraocular
retinoblastoma: the case for a new group classification. Ophthalmol Clin North
Am. 2005; 18: 4153.
5. Shields CL, Shields JA. Basic
understanding of current classification and management of retinoblastoma. Curr Opin
Ophthalmol. 2006; 17: 228234.
6. Houston SK, Pina Y, Scott WK, et al.
Regional and Temporal Differences in the Genetic Expression of LHBETATAG Retinoblastoma Tumors. Presented at
the Association for Research in Vision and Ophthalmology (ARVO) Meeting; Ft
Lauderdale, FL. May, 2010; 2010.
7. Kivela T. The epidemiological challenge
of the most frequent eye cancer: retinoblastoma, an issue of birth and death. Br
J Ophthalmol. 2009; 93: 11291131.
8. Broaddus E, Topham A, Singh AD.
Incidence of retinoblastoma in the USA: 19752004. Br J Ophthalmol. 2009; 93: 2123.
9. Seregard S, Lundell G, Svedberg H, Kivela
T. Incidence of retinoblastoma from 1958 to 1998 in Northern Europe:
advantages of birth cohort analysis. Ophthalmology, 2004; 111: 12281232.
10. MacCarthy A, Birch JM, Draper GJ, et al.
Retinoblastoma in Great Britain 1963 2002. Br J Ophthalmol. 2009; 93: 3337.
11. Schvartzman E, Chantada G, Fandino A, de
Davila MT, Raslawski E, Manzitti J. Results of a stage-based protocol for
the treatment of retinoblastoma. J Clin Oncol. 1996; 14: 15321536.
12. Carlos LL, Roberto RL, Victor TG, Carlos
HG, Eduardo LP. Risk of dying of retinoblastoma in Mexican children. Med
Pediatr Oncol. 2002; 38: 211213.
13. Leal-Leal C, Flores-Rojo M, Medina-Sanson
A, et al. A multicentre report from the Mexican Retinoblastoma Group. Br J
Ophthalmol. 2004; 88: 10741077.
14. Naseripour M, Nazari H, Bakhtiari P,
Modarres-zadeh M, Vosough P, Ausari M. Retinoblastoma in Iran: outcomes in
terms of patients survival and globe survival. Br J Ophthalmol. 2009; 93: 2832.
15. Kao LY, Su WW, Lin YW. Retinoblastoma
in Taiwan: survival and clinical characteristics 19782000. JPN J Ophthalmol. 2002;
46: 577580.
16. Chang CY, Chiou TJ, Hwang B, Bai LY, Hsu
WM, Hsieh YL. Retinoblastoma in Taiwan: survival rate and prognostic
factors. JPN J Ophthalmol. 2006; 50: 242249.
17. Swaminathan R, Rama R, Shanta V.
Childhood cancers in Chennai, India, 19902001: incidence and survival. Int J
Cancer, 2008; 122: 26072611.
18. Wessels G, Hesseling PB. Outcome of
children treated for cancer in the Republic of Namibia. Med Pediatr Oncol. 1996;
27: 160164.
19. Bowman RJ, Mafwiri M, Luthert P, Luande J,
Wood M. Outcome of retinoblastoma in east Africa. Pediatr Blood Cancer, 2008;
50: 160162.
20.. Kaneko
A, Suzuki S. Eye preservation treatment of retinoblastoma with vitreous
seeding. JPN J Clin Oncol. 2003; 33: 601-7.
21. Suzuki
S, Kaneko A. Management of intraocular retinoblastoma and ocular prognosis.
Int J Clin Oncol. 2004; 9: 1-6.
22 Abramson
DH, Dunkel IJ, Brodie SE, Kim JW, Gobin YP. A phase I/II study of direct
intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular
retinoblastoma initial results. Ophthalmology, 2008; 115: 1398-404, 1404.e1.
23. Gobin
YP, Dunkel IJ, Marr BP, Brodie SE, Abramson DH. Intra-arterial chemotherapy for the management of
retinoblastoma: Four-year experience. Arch Ophthalmol. 2011; 129: 732-7.
24. Muen
WJ, Kingston JE, Robertson F, Brew S, Sagoo MS, Reddy MA. Efficacy and
complications of super-selective intra-ophthalmic artery melphalan for the
treatment of refractory retinoblastoma. Ophthalmology, 2012; 119: 611-6.
25. Abramson
DH, Marr BP, Francis JH, Dunkel IJ, Fabius AW, Brodie SE, et al.
Simultaneous bilateral ophthalmic artery chemosurgery for bilateral
retinoblastoma (Tandem Therapy). PLoS One, 2016; 11: e0156806.
26. Chen
M, Zhao J, Xia J, Liu Z, Jiang H, Shen G, Li H, Jiang Y, Zhang J. Intra-arterial
chemotherapy as primary therapy for retinoblastoma in infants less than 3
months of age: A series of 10 cases. PLoS One 2016; 9: 11(8).
27. Shields CL,
Say EA, Pointdujour-Lim R, Cao C, Jabbour PM, Shields JA. Rescue intra-arterial chemotherapy following
retinoblastoma recurrence after initial intra-arterial chemotherapy. J Fr
Ophtalmol. 2015; 38: 542-9.
28. Shields
CL, Alset AE, Say EA, Caywood E, Jabbour P, Shields JA. Retinoblastoma
control with primary intra-arterial chemotherapy: Outcomes before and during
the intravitreal chemotherapy era. J Pediatr Ophthalmol Strabismus, 2016; 53: 275-84.
29. Yannuzzi
NA, Francis JH, Marr BP, Belinsky I, Dunkel IJ, Gobin YP, et al.
Enucleation vs. ophthalmic artery chemosurgery for advanced intraocular
retinoblastoma: A retrospective analysis. JAMA Ophthalmol. 2015; 133: 1062-6.
30. Rishi
P, Sharma T, Koundanya V, Bansal N, Saravanan M, Ravikumar R, et al. Intra-arterial
chemotherapy for retinoblastoma: First Indian report. Indian J Ophthalmol. 2015;
63: 331-4.
31. C
L Shields, E M Fulco, J D Arias, C Alarcon, M Pellegrini, P
Rishi, S
Kaliki, C G Bianciotto, and J. A Shields.
Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and
intravitreal chemotherapy Eye, 2013; 27: 253-264.
32. Inomata
M, Kaneko A. Chemo sensitivity profiles of primary and cultured human
retinoblastoma cells in a human tumor clonogenic assay. JPN J Cancer Res. 1987;
78: 858-68.
33. Brodie
SE, Munier FL, Francis JH, Marr B, Gobin YP, Abramson DH. Persistence of
retinal function after intravitreal melphalan injection for retinoblastoma. Doc
Ophthalmol. 2013; 126: 79-84.
34. Shields CL, Manjandavida FP, Arepalli S,
Kaliki S, Lally SE, Shields JA. Intravitrealmelphalan for persistent or
recurrent retinoblastoma vitreous seeds: Preliminary results. JAMA Ophthalmol. 2014;
132: 319-25.
35. Ghassemi
F, Shields CL, Ghadimi H, Khodabandeh A, Roohipoor R. Combined
intravitrealmelphalan and topotecan for refractory or recurrent vitreous
seeding from retinoblastoma. JAMA Ophthalmol. 2014; 132: 936-41.
36. Francis
JH, Schaiquevich P, Buitrago E, Del Sole MJ, Zapata G, Croxatto JO, et al.
Local and systemic toxicity of intravitrealmelphalan for vitreous seeding in
retinoblastoma: A preclinical and clinical study. Ophthalmology, 2014; 121: 1810-7.